Exclusive Summary

• **Novel Mechanism Targeting Refractory Cases**: UB125 is a novel GABAA receptor positive allosteric modulator acting on a non-benzodiazepine site, offering a potential solution for the 30% of patients with drug-resistant epilepsy.
• **Superior Preclinical Efficacy**: Demonstrated distinct superiority over standard-of-care drugs (Sodium Valproate, Phenytoin) in PTZ, KA, and Pilocarpine epilepsy models with profound dose-dependent efficacy.
• **Strategic Dual-Formulation**: Developed as both Oral (UB125) and Injection (UB125') prodrugs sharing the same active metabolite, covering both acute rescue and chronic maintenance markets.
• **Clean Safety Profile**: Preclinical data indicates no hERG inhibition (cardiac safety), no mutagenicity, and a wide therapeutic window, potentially overcoming toxicity issues of traditional anti-epileptics.

Asset Materials

Contact Us for Full Materials